
    
      This study is designed to examine the long term safety and efficacy of weekly subcutaneously
      injected albiglutide in combination with a single oral antidiabetic drug for 52 weeks in
      Japanese subjects with type 2 diabetes mellitus. Subjects with a historical diagnosis of type
      2 diabetes mellitus who are inadequately controlled on a single oral antidiabetic agent will
      be recruited into the study. Subjects will continue on their single antidiabetic agent and
      once weekly albiglutide will be added.
    
  